Open Access. Powered by Scholars. Published by Universities.®
Medicinal and Pharmaceutical Chemistry Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Medical Sciences (3)
- Pharmaceutics and Drug Design (3)
- Life Sciences (2)
- Medical Pharmacology (2)
- Natural Products Chemistry and Pharmacognosy (2)
-
- Alternative and Complementary Medicine (1)
- Biochemistry (1)
- Biochemistry, Biophysics, and Structural Biology (1)
- Diseases (1)
- Health Services Research (1)
- Health and Medical Administration (1)
- Internal Medicine (1)
- Laboratory and Basic Science Research (1)
- Medical Biochemistry (1)
- Medical Cell Biology (1)
- Medical Education (1)
- Medical Molecular Biology (1)
- Medical Neurobiology (1)
- Medical Specialties (1)
- Medicinal Chemistry and Pharmaceutics (1)
- Mental and Social Health (1)
- Molecular Biology (1)
- Molecular and Cellular Neuroscience (1)
- Nervous System Diseases (1)
- Neuroscience and Neurobiology (1)
- Neurosciences (1)
- Other Life Sciences (1)
- Keyword
-
- Acute kidney injury (1)
- Aminoglycoside (1)
- Binding Site Identification (1)
- Chloride Gradient Homeostasis (1)
- Drug Design (1)
-
- Early onset sepsis (1)
- GABAergic Inhibitory Signaling (1)
- Gentamicin (1)
- In Silico Hit Identification (1)
- Iterative R-Group Lead Optimization (1)
- KCC2 (Potassium–Chloride Cotransporter) (1)
- KCC2; Substance Abuse (1)
- Late onset sepsis (1)
- Machine Learning Medicinal Chemistry (1)
- Medicinal Chemistry (1)
- Molecular Dynamics Modeling (1)
- NICU (1)
- Neonatal sepsis (1)
- Neonate (1)
- Neuroscience (1)
- Opioid Use Disorder (OUD) (1)
- Renal function (1)
- Structural Biology (1)
- Structure-Based Drug Discovery and Development (1)
- Troughs (1)
- Urine output (1)
Articles 1 - 6 of 6
Full-Text Articles in Medicinal and Pharmaceutical Chemistry
Optimization Of A Kcc2 Small Molecule Agonist And The Development Of An In-Silico Model Of Intermolecular Dynamics For The Rational Design Of Therapeutics Against Opioid Use Disorder, William H.D. Ho, Alfred Amendolara, Kenyon Mitchell, Jaden Miner, Braxton Bingham, Andrew Payne
Optimization Of A Kcc2 Small Molecule Agonist And The Development Of An In-Silico Model Of Intermolecular Dynamics For The Rational Design Of Therapeutics Against Opioid Use Disorder, William H.D. Ho, Alfred Amendolara, Kenyon Mitchell, Jaden Miner, Braxton Bingham, Andrew Payne
Annual Research Symposium
Roseman University Research Symposium
Wednesday, February 18, 2026 | 3:00 – 6:00 pm (local time)
Neonatal Sepsis: Empiric Treatment And Monitoring Of Gentamicin Troughs In The Nicu, Aleese Palfreyman
Neonatal Sepsis: Empiric Treatment And Monitoring Of Gentamicin Troughs In The Nicu, Aleese Palfreyman
Annual Research Symposium
No abstract provided.
In-Silico Modeling And Characterization Of Kcc2 Protein Interaction With A Small Molecule Direct Agonist Identifies Potential Binding Sites For Modulating Behaviors Associated With Substances Of Abuse, William Hai Dang Ho, Alfred Amendolara, Kenyon Mitchell, Jaden Miner, Ruth Northcott, Braxton Bingham, Andrew J. Payne
In-Silico Modeling And Characterization Of Kcc2 Protein Interaction With A Small Molecule Direct Agonist Identifies Potential Binding Sites For Modulating Behaviors Associated With Substances Of Abuse, William Hai Dang Ho, Alfred Amendolara, Kenyon Mitchell, Jaden Miner, Ruth Northcott, Braxton Bingham, Andrew J. Payne
Annual Research Symposium
Purpose
KCC2 is a potassium-chloride cotransporter that plays a critical role in neuronal function by regulating GABAergic signaling via chloride gradients. Maintaining this concentration gradient is crucial for balancing excitation and inhibition in the brain. While KCC2 dysregulation has been implicated in epilepsy and seizures, recent studies suggest that KCC2 inhibition results in phenotypes mirroring those seen in chronic opioid dependence. As such, increasing evidence support KCC2 being a potential therapeutic target for modulating behaviors associated with substances of abuse. Currently, only a few direct small molecule agonists against KCC2 have been reported, and no definitive active site on the …
Development Of A Method For Identifying And Quantifying Epicatechin In Cinnamon Extract Supplement Capsules, Danielle Valls
Development Of A Method For Identifying And Quantifying Epicatechin In Cinnamon Extract Supplement Capsules, Danielle Valls
Annual Research Symposium
No abstract provided.
A Ligand-Based Approach To Identifying Commercially Available Inhibitors Of Human Galactokinase (Galk), Tyler Rose
A Ligand-Based Approach To Identifying Commercially Available Inhibitors Of Human Galactokinase (Galk), Tyler Rose
Annual Research Symposium
The purpose of this project was to find inhibitors of the human galactokinase (GALK) enzyme. GALK is responsible for catalyzing the conversion of galactose to galactose 1-phosphate, the first step in galactose metabolism. Galactose 1-phosphate builds up in the cells of patients with type 1 galactosemia due a genetic disorder. It has been proposed that inhibiting galactose 1-phosphate production by GALK may prevent many of the major complications of type 1 galactosemia. In this study, a ligand-based approach was used to identify commercially available inhibitors of GALK, starting from galactose-bearing natural products. Candidate inhibitors were screened for their ability to …
C38: Exploring Doxorubicin-Mediated Hypertrophy And Cell Death In Primary Human Cardiomyocytes, Sonia Phan
C38: Exploring Doxorubicin-Mediated Hypertrophy And Cell Death In Primary Human Cardiomyocytes, Sonia Phan
Annual Research Symposium
No abstract provided.